# Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites

> **NCT06759064** · PHASE1,PHASE2 · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 24 (estimated)

## Conditions studied

- Cancer of Stomach, Adenocarcinoma
- Ascites, Malignant

## Interventions

- **DRUG:** zoledronic acid plus Sintilimab intraperitoneal injection

## Key facts

- **NCT ID:** NCT06759064
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-12
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759064, "Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06759064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*